Our campaign launched high-throughput NaV1.9 assays which enable our customers to accelerate discovery of novel, non-opioid pain therapeutics with greater efficiency and confidence.
Our campaign launched high-throughput NaV1.9 assays which enable our customers to accelerate discovery of novel, non-opioid pain therapeutics with greater efficiency and confidence.
This nomination recognises the outstanding performance of Metrion’s commercial team during the company’s 10th anniversary year, a period that also presented significant challenges across the global life sciences industry.
Cost-effective expertise during critical phases of research, without sacrificing quality
Beth Sharp, Biomedical Sciences student at the University of Manchester, reviews her industrial placement year at Metrion
'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.
Students learned about electrophysiology concepts, sodium channels in drug discovery and the commercial business-side of ion channels
Review of CICF, bringing together a dynamic community of experts in ion channel research
In light of the FDA’s changing stance, the Volta assay emerges as a powerful, validated NAM capable of addressing the very safety concerns traditionally assessed in animal studies.
Robust and stable hNaV1.9 cell line delivering high-quality reproducible data allowing rapid hit identification, hit expansion and SAR
Robust and stable hNaV1.9 cell line delivering high-quality reproducible data allowing rapid hit identification, hit expansion and SAR